AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23638438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pesticide exposure
Number of subjects: 0
Study 23638438 — intervention group
Group type: EXPERIMENTAL
Intervention: Having an additional job off the farm
Number of subjects: 0
Study 23638438 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 0
Study 23638438 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous injury
Number of subjects: 0
Study 22087077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 4116
Study 22087077 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ASAQ)
Number of subjects: 4116
Study 22087077 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 4116
Study 22087077 — intervention group
Group type: COMPARATOR
Intervention: Chlorproguanil-dapsone-artesunate (CD+A)
Number of subjects: 4116
Study 18831979 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gainers (males)
Number of subjects: 2753
Study 18831979 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight losers (males)
Number of subjects: 2753
Study 18831979 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gainers (females)
Number of subjects: 2753
Study 18831979 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight losers (females)
Number of subjects: 2753
Study 18831979 — intervention group
Group type: COMPARATOR
Intervention: Weight maintainers (females)
Number of subjects: 2753
Study 17690340 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG
Number of subjects: 571
Study 17690340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix of four bacterial strains (L delbrueckii var bulgaricus, Streptococcus thermophilus, L acidophilus, and Bifidobacterium bifidum)
Number of subjects: 571
Study 17690340 — intervention group
Group type: COMPARATOR
Intervention: Oral rehydration solution (control group)
Number of subjects: 571
Study 17690340 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 571
Study 17690340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii
Number of subjects: 571
Study 17690340 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcus faecium SF68
Number of subjects: 571
Study 15331124 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone or hydrocortisone co-incubation
Number of subjects: 93
Study 15331124 — intervention group
Group type: COMPARATOR
Intervention: LPS stimulation
Number of subjects: 93
Study 11306905 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (110‐285 IU/kg/day) administered via continuous intravenous infusion after surgery until mobilization the next day
Number of subjects: 68
Study 11306905 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (150‐199 IU/kg/day)
Number of subjects: 68
Study 11306905 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (200‐285 IU/kg/day)
Number of subjects: 68
Study 11306905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 68
Study 9442423 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (0.3% triclosan, 2% copolymer, 1100 ppm F from 0.243% sodium fluoride)
Number of subjects: 60
Study 9442423 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (identical to test group but without triclosan/copolymer)
Number of subjects: 60
Study 7899035 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanding dynamic random-dot patterns
Number of subjects: 0
Study 7899035 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating dynamic random-dot patterns
Number of subjects: 0
Study 7899035 — intervention group
Group type: EXPERIMENTAL
Intervention: Translating dynamic random-dot patterns
Number of subjects: 0
Study 3232799 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms/kg
Number of subjects: 80
Study 3232799 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 micrograms/kg
Number of subjects: 80
Study 3232799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg
Number of subjects: 80
Study 3232799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms/kg
Number of subjects: 80
Study 3232799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms/kg
Number of subjects: 80
Study 2371371 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light at 10,000 lux for 30 minutes
Number of subjects: 24
Study 2371371 — intervention group
Group type: COMPARATOR
Intervention: Evening light at 10,000 lux
Number of subjects: 24
Study 2371371 — intervention group
Group type: COMPARATOR
Intervention: Morning light at 3,000 lux
Number of subjects: 24
Study 2371371 — intervention group
Group type: COMPARATOR
Intervention: 2,500 lux treatment for 2 hours (previous studies)
Number of subjects: 24
Study 1095308 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen (BC 105)
Number of subjects: 0
Study 1095308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31670808 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg plus Azithromycin 1 g
Number of subjects: 279
Study 31670808 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg plus Azithromycin 1 g
Number of subjects: 279
Study 31134866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural Response System using Community-Based Action Teams 'COMBAT' for preventing VAW
Number of subjects: 3280
Study 31134866 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 3280
Study 28780886 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal landing instruction
Number of subjects: 24
Study 28780886 — intervention group
Group type: COMPARATOR
Intervention: No verbal landing instruction
Number of subjects: 24
Study 28780886 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipodal landing
Number of subjects: 24
Study 28780886 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipodal landing
Number of subjects: 24
Study 24972643 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and drug addictions
Number of subjects: 360
Study 24972643 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic opinion about the causes and treatment of schizophrenia, anxiety, bulimia, and depression
Number of subjects: 360
Study 23558598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic treatment based on impedance cardiography
Number of subjects: 128
Study 21108561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NT‐proBNP measurement
Number of subjects: 4264
Study 21108561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NT‐proBNP measurement corrected for hs‐CRP
Number of subjects: 4264
Study 21108561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hs‐CRP measurement
Number of subjects: 4264
Study 21108561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hs‐CRP measurement corrected for NT‐proBNP
Number of subjects: 4264
Study 21108561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hs‐CRP adjusted for cardiovascular risk factors
Number of subjects: 4264
Study 21108561 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum NT‐proBNP adjusted for cardiovascular risk factors
Number of subjects: 4264
Study 19845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin treatment (Group I)
Number of subjects: 734
Study 19845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin withdrawal (Group II)
Number of subjects: 734
Study 19845417 — intervention group
Group type: COMPARATOR
Intervention: No vigabatrin treatment (Group III)
Number of subjects: 734
Study 19845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Groups I and II
Number of subjects: 734
Study 19845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of vigabatrin therapy
Number of subjects: 734
Study 19845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean daily dose of vigabatrin
Number of subjects: 734
Study 19845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 734
Study 19845417 — intervention group
Group type: EXPERIMENTAL
Intervention: Static perimetry vs kinetic perimetry
Number of subjects: 734
Study 17238670 — intervention group
Group type: EXPERIMENTAL
Intervention: RuleEd web-based editing environment
Number of subjects: 0
Study 15507097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Pangramin SLIT; 0.5 microg major allergens, three times per week for 32 months
Number of subjects: 97
Study 15507097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 97
Study 15507097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 11136681 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of enoxaparin during predilation with reduced systemic heparinization
Number of subjects: 100
Study 11136681 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparinization
Number of subjects: 100
Study 11136681 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of enoxaparin
Number of subjects: 100
Study 9232300 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 MAC isoflurane
Number of subjects: 67
Study 9232300 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 MAC isoflurane
Number of subjects: 67
Study 9232300 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (2 puffs)
Number of subjects: 67
Study 9232300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 puffs)
Number of subjects: 67
Study 8124904 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily morning administration of prednisolone
Number of subjects: 44
Study 8124904 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day administration of prednisolone
Number of subjects: 44
Study 8124904 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment in patients with GCA
Number of subjects: 44
Study 3301614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol enemas
Number of subjects: 45
Study 3301614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose enemas
Number of subjects: 45
Study 3301614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol and lactose enemas
Number of subjects: 45
Study 3301614 — intervention group
Group type: COMPARATOR
Intervention: Tap-water enemas
Number of subjects: 45
Study 30982843 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) - 155 units, 31 injections
Number of subjects: 179
Study 30982843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 179
Study 30982843 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA)
Number of subjects: 179
Study 27770336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 32
Study 27770336 — intervention group
Group type: COMPARATOR
Intervention: Casting
Number of subjects: 32
Study 26503066 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylethanol (PEth)
Number of subjects: 160
Study 26503066 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-deficient transferrin (CDT)
Number of subjects: 160
Study 23288418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (0.7 ml/kg)
Number of subjects: 90
Study 23288418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (0.6 ml/kg)
Number of subjects: 90
Study 23288418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (0.5 ml/kg)
Number of subjects: 90
Study 23288418 — intervention group
Group type: COMPARATOR
Intervention: Standard contrast protocol with test bolus technique
Number of subjects: 90
Study 21769850 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg administered twice a day
Number of subjects: 10
Study 21769850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18382907 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 211
Study 18382907 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 211
Study 16879825 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial stromal cells from patients with deep infiltrating endometriosis
Number of subjects: 99
Study 16879825 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial stromal cells from patients with ovarian endometriosis
Number of subjects: 99
Study 16879825 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial stromal cells from patients with superficial peritoneal endometriosis
Number of subjects: 99
Study 16879825 — intervention group
Group type: COMPARATOR
Intervention: Control endometrial tissue samples from fertile women
Number of subjects: 99
Study 12567339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 microg/mL) instilled for 20 seconds
Number of subjects: 103
Study 12567339 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine (5 microg/mL) instilled for 60 seconds
Number of subjects: 103
Study 12567339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal and iliohypogastric block with 0.25% bupivacaine with epinephrine
Number of subjects: 103
Study 12567339 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.25 mL/kg instilled for 20 or 60 seconds
Number of subjects: 103
Study 10469751 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 2091
Study 8700737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led unit
Number of subjects: 71
Study 8700737 — intervention group
Group type: COMPARATOR
Intervention: Medically managed care
Number of subjects: 71
Study 1832904 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical CMF (cyclophosphamide/methotrexate/5‐fluorouracil)
Number of subjects: 0
Study 1832904 — intervention group
Group type: COMPARATOR
Intervention: Intravenous CMF (modified 3-weekly schedule)
Number of subjects: 0
Study 6349648 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (200 mg initially, then 100 mg every 4 hours for 24 hours, followed by 100 mg every 8 hours for 6 days)
Number of subjects: 20
Study 6349648 — intervention group
Group type: COMPARATOR
Intervention: Indometacin (25 mg initially, then 25 mg every 4 hours for 24 hours, followed by 50 mg every 8 hours for 6 days)
Number of subjects: 20
Study 6349648 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium
Number of subjects: 20
Study 6349648 — intervention group
Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 20
Study 30563481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with good quality implementation of physical activity breaks, implemented by teachers with high self-efficacy and good previous knowledge about the intervention.
Number of subjects: 51
Study 30563481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with unsatisfying quality of implementation and low previous knowledge about the intervention.
Number of subjects: 51
Study 30563481 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with fewer physical activity breaks combined with other conditions.
Number of subjects: 51
Study 30563481 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 classes).
Number of subjects: 51
Study 27655755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 2000 IU/d
Number of subjects: 57
Study 27655755 — intervention group
Group type: COMPARATOR
Intervention: Cholecalciferol 400 IU/d
Number of subjects: 57
Study 24548977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 30
Study 24548977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22555530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated oil applied to surgical wound
Number of subjects: 20
Study 22555530 — intervention group
Group type: COMPARATOR
Intervention: Non-ozonated oil (control)
Number of subjects: 20
Study 20964865 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml/day anti‐inflammatory dose fish oil (3.6 g eicosapentaenoic acid, 2.4 g docosahexanoic acid)
Number of subjects: 150
Study 20964865 — intervention group
Group type: COMPARATOR
Intervention: 20 ml/day low dose fish oil (0.36 g eicosapentaenoic acid, 0.24 g docosahexanoic acid)
Number of subjects: 150
Study 18719436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative acceleromyographic monitoring
Number of subjects: 185
Study 18719436 — intervention group
Group type: COMPARATOR
Intervention: Qualitative train‐of‐four (TOF) monitoring
Number of subjects: 185
Study 15990174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronate receptor (CD44) expression during relapses
Number of subjects: 24
Study 15990174 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrin alpha4 (CD49d) expression during relapses
Number of subjects: 24
Study 12727401 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy
Number of subjects: 0
Study 12727401 — intervention group
Group type: COMPARATOR
Intervention: Open haemorrhoidectomy
Number of subjects: 0
Study 9450771 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a; AVONEX), 30 microg once weekly by intramuscular injection
Number of subjects: 0
Study 9450771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9450771 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a; AVONEX)
Number of subjects: 0
Study 9450771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (active patients with gadolinium enhancement at baseline)
Number of subjects: 0
Study 9450771 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a; AVONEX) (active patients with gadolinium enhancement at baseline)
Number of subjects: 0
Study 7887548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with three or more daily insulin injections or continuous subcutaneous insulin infusion guided by four or more glucose tests per day
Number of subjects: 1441
Study 7887548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study 7887548 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with one or two daily insulin injections
Number of subjects: 1441
Study 2223115 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve block (CEINB) with 0.5% bupivacaine
Number of subjects: 46
Study 2223115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CEINB)
Number of subjects: 46
Study 358371 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus BCG
Number of subjects: 63
Study 358371 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 63
Study 30951847 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic motor imagery of left and right finger extension
Number of subjects: 21
Study 30951847 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-machine interface with passive hand opening by a robotic orthosis
Number of subjects: 21
Study 30951847 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery and proprioceptive feedback
Number of subjects: 21
Study 30951847 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 21
Study 27890660 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing before biopsy
Number of subjects: 122
Study 27890660 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing after biopsy (completed within first 6 days)
Number of subjects: 122
Study 27890660 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing before biopsy
Number of subjects: 122
Study 27890660 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing after biopsy
Number of subjects: 122
Study 26192813 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable fixation system (Inion CPS)
Number of subjects: 230
Study 26192813 — intervention group
Group type: COMPARATOR
Intervention: Titanium fixation system (KLS Martin)
Number of subjects: 230
Study 24029029 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 24029029 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 20538475 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow gastric tube reconstruction (NGT group, n=52)
Number of subjects: 104
Study 20538475 — intervention group
Group type: COMPARATOR
Intervention: Whole stomach reconstruction (WS group, n=52)
Number of subjects: 104
Study 19680634 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.5 mg/kg)
Number of subjects: 9
Study 19680634 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.75 mg/kg)
Number of subjects: 9
Study 19680634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 9
Study 17898405 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Number of subjects: 42
Study 17898405 — intervention group
Group type: COMPARATOR
Intervention: Combined deep and superficial cervical plexus block
Number of subjects: 42
Study 15209006 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA fortified soy sauce
Number of subjects: 0
Study 15209006 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11684933 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of isoniazid (INH)
Number of subjects: 2736
Study 11684933 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of INH plus rifampicin (3HR)
Number of subjects: 2736
Study 11684933 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of INH plus rifampicin and pyrazinamide (3HRZ)
Number of subjects: 2736
Study 11684933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rifampicin-containing regimens (3HR and 3HRZ)
Number of subjects: 2736
Study 11684933 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of isoniazid (INH) among anergic subjects
Number of subjects: 2736
Study 11684933 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 2736
Study 9041901 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpolio group (N=121)
Number of subjects: 181
Study 9041901 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpolio syndrome (N not specified)
Number of subjects: 181